Fasenra pen 30 MG/mlml
Ended Awarded Last action
- Contract number
- SPE2DR26FQLP0
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $2,494
Award facts
- Contract value 100% obligated
- $2,493.75 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $2,493.75 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Fasenra Pen 30 mg/mL. This firm fixed-price delivery order, issued on January 20, 2026, with an ultimate completion date of January 21, 2026, was awarded without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award was issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy that establishes multiple regional prime vendor contractors to supply pharmaceutical products and medical consumables to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has served as a critical supplier within the federal pharmaceutical supply chain since its registration in the System for Award Management in 2001. The company's IDC with the Defense Logistics Agency, designated as contract SPE2DR and awarded on November 13, 2025, carries a ceiling value of $499,999,999 and extends through December 31, 2036, with a 30-month base period and three 30-month option periods. The contractor's extensive product portfolio includes branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables, and its demonstrated performance on numerous prior delivery orders spanning therapeutic categories from oncology treatments to emergency medications reflects its capability to fulfill the specialized pharmaceutical requirements of military healthcare operations globally.
Quick answers
Who was awarded contract SPE2DR26FQLP0?
SPE2DR26FQLP0 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 20, 2026.
How much is contract SPE2DR26FQLP0 worth?
The government has obligated $2,494 on SPE2DR26FQLP0.
Is contract SPE2DR26FQLP0 an order under another contract?
Yes. SPE2DR26FQLP0 is a delivery order under SPE2DR25D9354, an indefinite delivery contract.
Was contract SPE2DR26FQLP0 competed?
The extent of competition for SPE2DR26FQLP0 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award